Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Corticosteroids for High Risk aGVHD
NCT04061876Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Chinese PLA General Hospital. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04061876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061876.